Biomira Inc. presented a preliminary analysis of its Canadian Phase IItrials of its Theratope vaccine in patients with advanced breast, ovarianand colorectal cancer. The data were presented earlier this month at theEighth Annual Stuttgart Symposium on Immunotherapy in Germany.Mark Reddish, director of immunology for the Edmonton, Alberta,company, said 48 percent, or 42 of the 87 evaluable patients, showednon-progressive disease, while suffering no toxic side effectsassociated with chemotherapy and radiation treatment.Biomira also reported on results from a physician-sponsored trial beingconducted by Jay Gold at Mount Sinai Hospital in New York. There, acombination of Theratope and other biomodulators, such as alpha-interferon and low dose mitomycin-C, were used on patients withchemotherapy-resistant breast and gastrointestinal cancers. Of 28evaluable patients, 73 percent of gastrointestinal patients and 71percent of those with breast cancer showed non-progressive disease."This is showing us we're headed in the right direction," Jane Jack,Biomira's investor relations coordinator, told BioWorld. "It'sconfirmation of data we presented earlier at our annual meeting [inMay]. This is just more mature data."The vaccine is a carbohydrate antigen attached to a carrier keyholelimpet. To further boost immunogenicity, the component then aremixed with Ribi ImmunoChem Research's adjuvant Detox. _ JimShrine
(c) 1997 American Health Consultants. All rights reserved.